Dicerna raises $60 million in series C

RNAi company Dicerna Pharmaceuticals Inc. (Watertown, Mass.) raised $60 million in a series C round led by new investor RA Capital. New investors Brookside Capital; Deerfield Capital; and Omega Funds also participated, along with existing investors Abingworth; Domain Associates; Oxford Bioscience Partners; Skyline Ventures; and SR One. RA Capital's Peter Kolchinsky joined Dicerna's board. ...